Fuzz ... "imho" your post = hammer on nail head

Challenges for BoM2 = money and hospital access & testing during a pandemic that has been dominating care in addition to emergencies.

However, this Covid pandemic alternately and opportunistically provides the quickest path forward to to an approvel/commercialization, that fits within the current state of healthcare priorities, given the MOA and focus of the world healthcare scene.

Upon Covid "success" potentially and hopefully ... comes a much better name for RVX and Apabetalone, proof of concept for epigenetics, money and options, and likely a highly renewed interest for partnering and maybe even buy out with a now proven commercial drug and company with a massive set of other "likely" and lucrative indications, a massive library of more molecules, strong IP and pipeline, patent protection, etc ... and strong bargaining position or realistic options for going it alone with Eversana.

Yes, Don and BoD appear to be betting the "pharm" on Covid, in a "stroke of luck" type timing opportunity. All jmho's of course from the mushroom patch.